Summary.-The urinary excretion patterns of oestrogen metabolites, including unusual metabolites, were determined by gas chromatography and mass spectrometry for 63 women with advanced breast cancer and 39 normal postmenopausal women. The concentration of total unusual metabolites excreted was found to be an excellent discriminant between breast-cancer patients and controls (P <0.0001).
Discrimination between responders and non-responders to endocrine therapy was attempted, using several different indices. Of these, the ratio of Classical Oestrogens to Unusual Metabolites (CE/UM) proved a fair discriminant, but the product of this ratio and the oestriol ratio (CE/UM x E3R) was much the best discriminant. This product, termed a Pattern Index, has considerable potential, not only as a discriminant for selecting therapy, but also as a rapid index of patient response to that therapy.
IT IS NOW WELL ESTABLISHED that the presence of functional oestrogen receptor in a biopsy sample of human breast cancer reflects both a good chance of response to endocrine therapy (Barnes et al., 1979; Edwards et al., 1979; Hawkins et al., 1980; 981a) and a better prognosis (Knight et al., 1977; Bishop et al., 1979; Hawkins et al., 1980; Leake et al., 1981b) . Before the advent of receptor analyses, several steroid metabolic discriminants were used, with varying degrees of success (Bulbrook et al., 1960; 1971; Lemon et al., 1966; MacMahon et al., 1971) , to identify potential responders to hormone therapy. Renewed interest in the metabolism of oestrogen in breast-cancer patients has arisen because certain of the hydroxymetabolites can bind oestrogen receptor without promoting target-cell growth (Martucci & Fishman, 1976) and so might act as protective agents against neoplastic induction by biologically active oestrogens. For example, 2-hydroxyoestrone has anti-oestrogenic action, and the ratio 2-hydroxyoestrone: oestradiol-1 7/ is much reduced in obese women, who constitute one of the high-risk groups (Fishman et al., 1975) . Besides, the relationship between dietary fat, oestrogen metabolism in adipose tissue and breast-cancer incidence is well recognized (Nimrod & Ryan, 1975) .
In a comprehensive review, Dao (1979) has argued that further analysis of abnormal, particularly polar, oestrogen metabolites in breast-cancer patients is urgently needed. We therefore undertook a study of excretion patterns of oestrogen metabolites, including unusual metabolites, in women with breast cancer, in relation to their response to endocrine therapy.
MATERIALS AND METHODS

Patients.
Sixty-three patients were studied: they were of mean age 60-3 + 8-6 years and 3-15 (mean 10-2 + 5.6) years postmenopausal. All had previously undergone mastectomy (simple or modified radical) but had no adjuvant therapy, nor other endocrine or cytotoxic therapy, during the 12 months before entry into this study. All had ad-vanced disease. Metastatic disease was found in 68% of cases, and 70% of this group had distant metastases. Patients with metastases which might directly influence steroid metabolism (i.e. in liver, ovaries or adrenal cortex) were excluded from this study.
On entry into the study each patient (a) gave 3 24h urine specimens over a 15-day period and (b) subsequently received additive endocrine therapy (5 mg t.d. diethyl stilbestrol or hexoestrol). As a control, similar urine samples were collected from 39 clinically normal postmenopausal women (mean age 61-1 + 6-4; mean years postmenopausal 9-8 + 5.2). All patients attended the Cancer Centre in Palermo for clinical assessment of response to treatment, which was made using UICC guidelines by a member of the Cancer Centre not involved in the study. For the purposes of this study, patients were classified as responders (complete plus partial response) and non-responders (static plus progressive disease).
Methods.-All materials were of Analar grade. Oestrone (E1), oestradiol-17/ (E2) and oestriol (E3) levels in urine samples were determined by gas chromatography (and additional mass spectrometry, where necessary) as described previously (Castagnetta et al., 1976; Paparopoli et al., 1977 ; see also Kodama & Kodama, 1975 Campbell, 1974 
RESULTS
Sixty-three patients with advanced breast cancer received endocrine therapy as sole therapy. Of these, 24 (38%) showed objective remission (complete or partial) using UICC criteria. Each patient had given 3 separate 24h urine samples before the start of therapy. Concentrations of steroid in each of the 3 samples were averaged and recorded as ,tg/24 h. Three similar urine samples were collected from each of 39 clinically normal women (Group C) and the steroid excretion patterns similarly determined.
For analysis of the results the breastcancer patients were divided into responders (R) and non-responders (NR) to endocrine therapy. For the 24 responders, mean age was 62-4 + 4*5 and mean years postmenopausal 12-4 + 3-8. For the 39 non-responders mean age was 58-6 + 7-4 and mean years postmenopausal 9.1 + 5-6. Then, in order to evaluate the statistical significance, if any, between the 3 groups (C, R and NR), steroid excretion was expressed as the logarithm of the mean value for total oestrogens, unusual metabolites and oestriol and as the square root for classical oestrogens. The results are shown in Table I . The data in Table I show that the most significant difference between steroid excretion by normal women and those with breast cancer is found by measuring unusual metabolites. None of the 39 controls secreted more than 10 Htg unusual metabolites in 24 h. However, 55/63 breast-cancer patients exceeded this figure. Similarly, a threshold value of 24 ,ug/24 h for total oestrogen excretion was exceeded by 54/63 breast-cancer patients, but by no controls. No good discriminant between responders and nonresponders is seen, though only 4/24 responders secreted more than 20 ,ug/24 h classical oestrogen, whereas 18 of the 39 non-responders did so.
In a further attempt to differentiate between responders and non-responders the oestriol ratio (E3R=E3/E1+E2) and the ratio of classical oestrogens to unusual metabolites (CE/UM) was calculated, as was the product of the two ratios (CE/ UM x E3R). The results are shown in Table II .
The data in Table II suggest that E3R (as opposed to oestriol excretion alone) gives some differentiation between responders and non-responders to endocrine therapy. This confirms well established data (Lemon et al., 1966; MacMahon et al., 1971) but is still inadequate to discriminate reliably between potential responders and non-responders (Dao, 1979; Castagnetta et al., 1980a) . The ratio CE/UM is clearly an excellent discriminant between breast cancer patients and control women.
Patients who subsequently were classified as responders also showed a rise in this ratio towards the control value during therapy, whereas non-responders did not (data not shown). This ratio might, therefore, prove very useful for monitoring early response to therapy. The product of the two ratios (CE/UM x E3R) is, perhaps, the best function for discriminating between responders and non-responders. We shall refer to it as the Pattern Index.
Applying the criteria of sensitivity and Tables I and II , and taking the following threshold values for each parameter, the Classical Oestrogens (< 20 ,ug/24 h) show good sensitivity in distinguishing responders (8333%) but mediocre specificity (4877%) while E3R (< 1.0) shows very good specificity (8466%) and only fair sensitivity (58.3 %); the only parameter which appears valid in both respects is the Pattern Index (< 2 0) which combines excellent sensitivity (9.1 70) with reasonable specificity (64.1 G,).
)ISCUSSION
Previous work on urinary-oestrogen excretion profiles in breast cancer has failed to identify a reliable discriminant between those who will respond to endocrine therapy and those who will not (Bulbrook et al., 1971) . E3R has been shown to discriminate well between breastcancer patients and controls (Lemon et al., 1966) and between different populations of women with different incidences of breast cancer (MacMahon et al., 1971) . However, the failure of E3R, and of other indices of oestrogen excretion, reliably to identify responders to endocrine therapy has led Dao (1979) to propose the investigation of excretion of unusual metabolites of oestrogen by breast-cancer patients.
From the present studies it is clear that excretion of unusual metabolites in significant quantities ( > 10 [g/24 h), though never seen in clinically normal women, is very common in breast-cancer patients (55/63). However, excretion of unusual metabolites cannot be taken as sole indication of breast cancer, but rather as an abnormality associated with endocrine disorders, because they are also excreted in endometrial and prostatic cancer (Castagnetta, 1979) and in some cases of gynaecomastia and fibrocystic mastopathy (Castagnetta et al., 1980b) (Martucci & Fishman, 1976) but suggests that they are products of metabolism within the tumour cell. Since they are excreted by both responders and nonresponders to endocrine therapy, this metabolism is presumably not related to the presence of receptor.
By combining excretion levels of classical oestrogens and of the unusual metabolites with the oestriol ratio (CE/UM x E3R; Table II ) it becomes possible to distinguish most responders from non-responders. The range of this Pattern Index is large, but the discrimination between responders and non-responders, in terms of both sensitivity (91-700) and specificity (64.1 %0) is good. Classical oestrogen excretion is, of course, age-dependent, but the mean ages of the 2 groups were reasonably comparable (62 for responders and 59 for non-responders).
One of the principal objectives of this study was to establish whether the concentration of unusual metabolites excreted was related to the oestrogenreceptor (RE) status of the tumour. Since the data in Table I suggest that similar concentrations of unusual metabolites are excreted by responders (R) and nonresponders (NR) to endocrine therapy and, further, since it is known that functional RE is normally associated with responding tumours (Barnes et al., 1979; Leake et al., 1] 979), a direct correlation between unusual-metabolite excretion and RE concentration is unlikely. Nevertheless, a close relationship between Pattern Index and RE status could be predicted, and appropriate studies are under way.
In conclusion, Pattern Index is a useful index of potential response to endocrine therapy. However, the principal current 673 use for studies of excretion of oestrogen metabolites, as described here, might be in early detection of the disease, especially in high-risk patients, and in monitoring response to therapy, especially in patients presenting with very advanced disease.
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